+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

From
Angiosarcoma Treatment - Global Strategic Business Report - Product Thumbnail Image

Angiosarcoma Treatment - Global Strategic Business Report

  • Report
  • June 2025
  • 390 Pages
  • Global
From
From
From
Research-Grade Proteins Market Report 2025 - Product Thumbnail Image

Research-Grade Proteins Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Head and Neck Cancer (HNC) Pipeline Analysis Report - Product Thumbnail Image

Head and Neck Cancer (HNC) Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Thumbnail Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Advanced Liver Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Liver Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
AXL Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

AXL Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Squamous Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Squamous Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
LAG-3 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

LAG-3 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
4-1BB Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

4-1BB Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
Tie-2 Modulators - Pipeline Insight, 2025 - Product Thumbnail Image

Tie-2 Modulators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Phaeochromocytoma - Pipeline Insight, 2025 - Product Thumbnail Image

Phaeochromocytoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
From
Mesothelioma - Pipeline Insight, 2025 - Product Thumbnail Image

Mesothelioma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more